Open Access Funding provided by Universitat Autonoma de Barcelona. COPPADIS and the present study were developed with the help of Fundación Española de Ayuda a la Investigación en Enfermedades Neurodegenerativas y/o de Origen Genético (https://fundaciondegen.org/) and Alpha Bioresearch (www.alphabioresearch.com). We also received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017–2020 por el Proyecto “PROGRESIÓN NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”) to develop a part of the COPPADIS project. JRA: has received honoraria for educational presentations by Zambon. SMH: SMH has received honoraria for lecturing from: Teva, Zambon, UCB, and Roche, and reports grants from Huntington’s disease Society of America (Human Biology Project), and from Fondo de Investigaciones Sanitarias (FIS) from Instituto de Salud Carlos III (ISCIII). APD: none. AHB: none. JP: has served on advisory or speakers' boards, and received honoraria from: UCB, Zambon, AbbVie, Italfarmaco, Allergan, Ipsen, Bial and reports grants from Fundació la Marato de TV3, Fondo de Investigaciones Sanitarias (FIS) and from Instituto de Salud Carlos III (ISCIII). TDF: none. SJ: has received honoraria from AbbVie, Bial, Merz, UCB, and Zambon and holds the competitive contract "Juan Rodés" supported by the Instituto de Salud Carlos III. She has received grants from the Spanish Ministry of Economy and Competitiveness (PI18/01898) and the Consejería de Salud de la Junta de Andalucía (PI-0459–2018). MC: none. JGC: has received honoraria for educational presentations and advice service by Qualigen, Nutricia, Abbvie, Italfarmaco, UCB Pharma, Lundbeck, Zambon, Bial, and Teva. MAAR: has received honoraria from Zambon, UCB Pharma, Qualigen, Bial, and Teva, and sponsorship from Zambon and Teva for attending conferences. NC: has received honoraria from Bial, Italfármaco, Qualigen, Zambon, UCB, Teva and KRKA and sponsorship from Zambon, TEVA and Abbvie for attending medical conferences. IL: has received honoraria for educational presentations and advice service by Qualigen, Nutricia, Abbvie, UCB Pharma, Zambon, Bial, and Teva. JHV: has received travel bursaries and educational grants from Abbvie and has received honoraria for educational presentations from Abbvie, Teva, Bial, Zambon, Italfarmaco, and Sanofi-Genzyme. IC: has received honoraria for educational presentations and advice service by Abbvie, Zambon, and Bial. LLM: compensated advisory services, consulting, research grant support, or speaker honoraria: AbbVie, Acorda, Bial, Intec Pharma, Italfarmaco, Pfizer, Roche, Teva, UCB, and Zambon. IGA: none. VGM: has received honoraria from Bial, Merz and Zambon for educational lectures. JGA: none. JDGS: compensated advisory services, consulting, research grant support, or speaker honoraria: Merck, Sanofi-Genzyme, Allergan, Biogen, Roche, UCB and Novartis. CB: none. BSV: has received honoraria for educational presentations and advice service by UCB, Zambon, Teva, Abbvie, Bial. MAS: has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Zambon, Bial, and Teva. LV: has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, and Teva. SE: has received honoraria for educational presentations and advice service by Abbvie, Zambon, and Bial. EC: Travel grants: Abbvie, Allergan, Boston; Lecturing honoraria: Abbvie, International Parkinson´s disease Movement Disorder Society. ZM: none. IP: has received honoraria from Lundbeck, Krka, TEVA, UCB, Zambon, Allergan, Ipsen, and Merz. PSA: has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, and Teva. MGAL: has received honoraria for educational presentations and advice service by Zambon and Bial. NLA: has received honoraria for educational presentations and advice service by Abbvie, Italfarmaco, Zambon, and Bial. IG: has received research support from Abbvie and Zambon and has served as a consultant for Abbvie, Exelts, and Zambon. JRM: has received honoraria for educational presentations, attending medical conferences, and advice service by Abbvie, UCB Pharma, Zam-bon, Italfarmaco, Bial, and Teva. MTB: none. CO: none. CV: has received honoraria for educational services from Zambon, Abbvie and UCB. VP: has served as consultant for Abbvie and Zambon; has received grant/research from Abbvie. MK: has received honoraria from Bial, the Spanish Neurology Society, and the International and Movement Disorders Society. MBE: has received honoraria for educational presentations and advice service by Abbvie, Abbott, UCB Pharma, Allergan, Zambon, Bial, and Qualigen. PMM: has received honoraria from Bial for lecturing in course and from the Parkinson and Movement Disorder Society (MDS) for management of the COA International Program of the Society. PM: has received honoraria from AbbVie, Abbott, Allergan, Bial, Merz, UCB, and Zambon and have received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Subdirección General de Evaluación y Fomento de la Investigación) and by Fondo Europeo de Desarrollo Regional (FEDER), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0437–2012, PI-0471–2013], the Sociedad Andaluza de Neurología, the Jacques and Gloria Gossweiler Foundation, the Fundación Alicia Koplowitz, the Fundación Mutua Madrileña. DSG: has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, Italfarmaco, Teva, Archímedes, Esteve, Stada, Merz, and grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017–2020 por el proyecto “PROGRESIÓN NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”; Concesión de Contrato para la intensificación de la actividad investigadora en el Sistema Nacional de Salud, Convocatoria 2021, Instituto de Salud Carlos III). CSG: none. JK: (1) Consulting fees: Roche, Zambon; (2) Stock / allotment: No; (3) Patent royalties / licensing fees: No; (4) Honoraria (e.g. lecture fees): Zambon, Teva, Bial, UCB; (5) Fees for promotional materials: No; (6) Research funding: Roche, Zambon, Ciberned; Instituto de Salud Carlos III; Fundació La Marató de TV3; (7) Scholarship from corporation: No; (8) Corporate laboratory funding: No; (9) Others (e.g. trips, travel, or gifts): No.